Last reviewed: June 20, 2026

Last updated: June 20, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide is a GLP-1 receptor agonist originally developed to treat type 2 diabetes, and clinical research shows it produces weight loss of 5–22% when used for metabolic management. However, not every patient is an appropriate candidate, and understanding eligibility criteria helps protect your health while maximizing treatment outcomes.

Who Qualifies for Semaglutide Therapy

Semaglutide eligibility begins with metabolic assessment rather than a fixed BMI threshold alone. Candidates typically include adults with a BMI of 30 or higher, or a BMI of 27+ with weight-related health conditions such as hypertension, type 2 diabetes, or sleep apnea. PlexusDx evaluates each patient's complete medical history, current medications, and lab markers to confirm safety and appropriateness before treatment initiation.

Age matters in semaglutide selection—the medication has been studied extensively in adults over 18, though data in older adults (70+) remains more limited. Kidney function, liver health, and thyroid status all influence whether semaglutide is right for you. PlexusDx providers perform thorough screening to identify contraindications and ensure your metabolic profile supports GLP-1 therapy safely.

Medical Conditions That May Affect Semaglutide Safety

A history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) is an absolute contraindication—semaglutide should never be used in these cases. Similarly, patients with acute pancreatitis, severe kidney disease (eGFR below 15), or untreated diabetic retinopathy require careful evaluation before starting therapy. PlexusDx providers review your complete clinical picture to identify these red flags during the qualification process.

Pregnancy and breastfeeding represent periods when semaglutide is not recommended, as safety data in these populations remains limited. Patients with a personal or family history of thyroid cancer require enhanced monitoring and may need alternative options. Additionally, those with a history of gallbladder disease or current gallstones should discuss risks with their PlexusDx provider, since rapid weight loss can sometimes trigger gallstone formation.

How PlexusDx Determines Your Semaglutide Candidacy

PlexusDx uses a detailed intake questionnaire, blood work review, and metabolic profiling to assess whether semaglutide injection (starting at $149/month) is appropriate for your goals and health status. This personalized approach looks beyond BMI to evaluate insulin resistance, inflammation markers, and thyroid function—all factors that influence treatment response and safety. Your PlexusDx provider then creates a tailored protocol that accounts for your unique physiology.

The Precision Peptide Genetic Test (available as a $99 add-on after your first month) identifies how your genes influence GLP-1 receptor sensitivity, dopamine reward pathways, and appetite regulation. This genetic insight helps PlexusDx refine dosing strategy and predict which patients may respond most favorably to semaglutide versus alternatives like tirzepatide or dual-compound protocols.

Common Reasons Patients Are Not Suitable for Semaglutide

Uncontrolled blood pressure above 180/110 mmHg may warrant treatment optimization before starting semaglutide, since the medication can affect cardiovascular tone. Patients with active eating disorders or a psychiatric history involving disordered eating patterns require careful screening and may benefit from concurrent mental health support rather than GLP-1 monotherapy. Similarly, those with severe gastroparesis (delayed stomach emptying) should avoid semaglutide, as it slows gastric transit further.

Severe dehydration, acute illness, or recent abdominal surgery are temporary contraindications that may resolve with time. Some patients on certain blood pressure medications or blood thinners need dose adjustments to semaglutide protocols. PlexusDx providers evaluate these factors comprehensively to ensure safe treatment initiation and ongoing monitoring throughout your weight loss journey.

What Happens During the Semaglutide Eligibility Screening

Your initial PlexusDx consultation includes a detailed health questionnaire covering medical history, current medications, family history of cancer or thyroid disease, and weight-loss goals. A PlexusDx provider reviews your responses and any recent lab work (within 6 months), checking kidney function, liver enzymes, fasting glucose, and thyroid markers. This thorough screening ensures you start semaglutide safely and helps identify patients who might benefit from alternative compounds or combination protocols.

Once approved, your PlexusDx provider prescribes compounded semaglutide injection from licensed 503A pharmacies, starting at $149 monthly with HSA/FSA eligibility. Your dose may increase over time to achieve optimal results—but your price remains flat across all tiers. PlexusDx then schedules follow-up check-ins to monitor tolerability, track weight loss progress, and adjust your protocol as needed.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can I take semaglutide if I have type 2 diabetes?

Yes—semaglutide is safe and often beneficial for patients with type 2 diabetes, as it lowers blood sugar while supporting weight loss. However, if you're already on diabetes medications, PlexusDx will monitor your glucose levels closely and adjust your diabetes regimen to prevent hypoglycemia. Always disclose all current medications during your eligibility screening.

What BMI do I need to qualify for semaglutide through PlexusDx?

PlexusDx considers BMI alongside other health factors—typically BMI 30+ qualifies, or BMI 27+ with weight-related conditions. However, eligibility isn't determined by BMI alone; your overall metabolic health, kidney function, and medical history all influence candidacy. Schedule a consultation with PlexusDx to discuss your specific situation.

Is semaglutide safe if I'm over 65 years old?

Semaglutide can be used in older adults, but PlexusDx requires careful evaluation of kidney function, heart health, and medication interactions, as these factors become more important with age. Clinical data in adults 70+ is more limited, so your provider will monitor you closely. Most adults over 65 can safely use semaglutide if cleared by their PlexusDx provider.

What are the most common reasons PlexusDx declines semaglutide eligibility?

The most frequent reasons include a personal or family history of medullary thyroid carcinoma, MEN2 syndrome, severe kidney disease, or active eating disorders. Uncontrolled high blood pressure, severe gastroparesis, and pregnancy also disqualify patients. If you're declined for semaglutide, PlexusDx may recommend tirzepatide, microdose GLP-1 protocols, or other personalized alternatives.

How does the Precision Peptide Genetic Test improve my semaglutide candidacy assessment?

The $99 Precision Peptide Genetic Test maps 49 peptides across 14 metabolic pathways, including GLP-1 receptor sensitivity (rs6923761) and appetite-regulation genes like MC4R and FTO. This genetic data helps PlexusDx predict your individual response to semaglutide versus tirzepatide and guides personalized dosing for maximum efficacy and safety.

Can I take semaglutide if I'm on blood pressure medication?

Yes, semaglutide is compatible with most blood pressure medications, but PlexusDx will review your specific drugs to check for interactions. Some patients experience blood pressure changes on semaglutide, so your provider may adjust your antihypertensive doses or monitor your BP more frequently during the initial weeks.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves